Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study
The PALOMA-3 Investigators
Research output: Contribution to journal › Article › peer-review
88Scopus
citations
Fingerprint
Dive into the research topics of 'Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study'. Together they form a unique fingerprint.
Keyphrases
Pharmacology, Toxicology and Pharmaceutical Science